Von Eschenbach Disappointed With Critical Path Progress
This article was originally published in The Pink Sheet Daily
FDA Commissioner tells Maryland biotech audience he wants FDA to be a bridge rather than a barrier to life science advances.
You may also be interested in...
Voluntary collaboration will help FDA develop quality standards for submission of microarray data.
Agency opportunities list highlights 76 “scientific projects” that could modernize the medical product development process.
Washington State Ecology Mulls ‘Safer’ Definition While Exploring Phthalate Alternatives In Fragrances
Marissa Smith, senior regulatory toxicologist in the Washington Department of Ecology’s Hazardous Waste and Toxics Reduction program, discusses what’s next for the state’s inaugural Safer Products go-round. “How we define ‘safer’ is really going to be the lynchpin of this whole process,” she says.